Navigation Links
Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Date:2/10/2011

political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.Contacts:Media:

Investors:Natalie deVane

Robert (Chip) Merritt610-727-6536

610-738-6376ndevane@cephalon.com

cmerritt@cephalon.comJoseph Marczely610-883-5894jmarczely@cephalon.comCEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)(Unaudited)Three Months EndedYear EndedDecember 31,December 31,2010200920102009REVENUES:Net sales

$ 764,759$ 562,938$ 2,760,952$ 2,151,548Other revenues

5,81012,17750,10540,760770,569575,1152,811,0572,192,308COSTS AND EXPENSES:Cost of sales

150,142105,204577,863398,837Research and development

122,39191,165439,995395,43
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- United Medical Education, ... Life Support (ACLS), Pediatric Advanced Life Support (PALS) and ... BLS and ACLS online course manuals. In ... simply need to build an account with the company. ... these programs, United Medical Education is setting a precedent ...
(Date:5/17/2013)... BOSTON , May 17, 2013  TechAtlas ... update for their competitive landscape map for the ... highlights over 90 international companies with drugs and ... addressing CKD and its sequelae. ... include: , hypertension - renal denervation ...
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 Rio ... has recently completed a stylish renovation that features tranquil, ... specialties. , From the ground up, this Morro ... with fresh flooring, soothing colors and comfortable spa beds. ... installed, including an Apilus epilator machine. The shampoo ...
(Date:5/18/2013)... 2013 Losing weight remains to be the ... horde of new weight loss products available in the market ... studies about this newest weight loss supplement prove that dieting ... , Garcinia Cambogia is a sub-tropical fruit that is shaped ... fruit can suppress a person’s appetite, while it effectively burns ...
(Date:5/18/2013)... 2013 Spectrum Surgical Instruments will ... 17-22 in Austin, TX where thousands of GI ... networking opportunities. , Spectrum Surgical/STERIS will feature ... repair capabilities and certified pre-owned equipment. Attendees ... on proper instrument care of flexible endoscopes. ...
Breaking Medicine News(10 mins):Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2
... Feb. 11 Abbott ( NYSE: ABT ),today ... Food and Drug,Administration (FDA) for its new, compact ... expand the company,s hematology,platform by offering a high ... laboratories. , As small ...
... Inc., a privately held company located in the Midwest, ... eliminates all of the most common problems associated with ... therapy hasn,t always been therapeutic for many people. The ... never continue therapy beyond the first night ... because ...
... Tibotec Therapeutics, a division of Centocor Ortho ... a lower-dose (75 mg) formulation of PREZISTA (darunavir) ... the FDA approval of PREZISTA, co-administered with ritonavir ... treatment of HIV infection in pediatric patients six ...
... Men, Women Differ in Oral Health Care Habits , CHICAGO, ... what do people find most attractive in others? The smile. ... Crest(R) and Oral B(R) finds that the smile outranked eyes, ... men and women differ when it comes to taking care ...
... Ongoing Study Shows Seven of 14 Evaluable Patients ... Two Treatment Cycles----Bavituximab Has Now Produced Positive Early ... Therapy Cancer Trials--TUSTIN, Calif., Feb. 11 Peregrine ... reported that its lead product candidate bavituximab achieved ...
... Sanofi-aventis announced today that Jean-Pierre ... Chief Medical Officer (CMO). He was previously Senior ... Marc Cluzel, Senior Vice President, Research & Development, who ... Officer is a further demonstration internally and externally of ...
Cached Medicine News:Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 3Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 4Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 5Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 6Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 7Health News:Survey Finds Smile is 'Most Attractive' Physical Feature 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 2Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 3Health News:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study 4Health News:Jean-Pierre Lehner Appointed Chief Medical Officer 2
...
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Adjustable lid speculum with mm blades. Miniature frame ideal for deep set eyes and small orbital structures....
Medicine Products: